SCHEMBL7056836

SCHEMBL7056836

CC(C)(C)[Si](C)(C)ONC(=O)[C@@H](CCc1ccccc1)NS(=O)(=O)Cc1ccc2ccccc2c1.O=C(NO)[C@@H](CCc1ccccc1)NS(=O)(=O)Cc1ccc2ccccc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 4/20 0.38
MMP1 P03956 3/20 0.38
MMP13 P45452 3/20 0.38
ADAM17 P78536 2/20 0.38
FCER2 P06734 4/20 0.37
TSHR P16473 1/20 0.36
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
MMP2 P08253 2/20 0.35
MMP3 P08254 1/20 0.35
CYP2D6 P10635 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
CASR P41180 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KCNH2 Q12809 1/20 0.35
F2 P00734 1/20 0.35
PLG P00747 1/20 0.35
PLAU P00749 1/20 0.35
ST14 Q9Y5Y6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7558927 0.96 ITGB3 (0.38) MMP9MMP1MMP13ITGB3ITGA2B
SCHEMBL7558929 0.96 ITGB3 (0.38) MMP9MMP1MMP13ITGB3ITGA2B
SCHEMBL6739657 0.86 TSHR (0.45) MMP9MMP1MMP13ADAM17FCER2
SCHEMBL6739658 0.86 TSHR (0.45) MMP9MMP1MMP13ADAM17FCER2
SCHEMBL6841965 0.77 MMP7 (0.48) MMP13ITGB3ITGA2BF2PLG
SCHEMBL6841969 0.77 MMP7 (0.48) MMP13ITGB3ITGA2BF2PLG
SCHEMBL6733013 0.74 MMP9 (0.48) MMP9MMP1MMP13ADAM17MMP2
SCHEMBL6733017 0.74 MMP9 (0.48) MMP9MMP1MMP13ADAM17MMP2
SCHEMBL6737622 0.73 MMP2 (0.40) MMP9MMP13TSHRMMP2F2
SCHEMBL6738691 0.73 MMP2 (0.40) MMP9MMP13TSHRMMP2F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 US disclosed
EP-1244616-A1 (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SmithKline Beecham plc (GB) 2002-10-02 EP disclosed
WO-2001047874-A1 (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives CD40, CD22, CD2 MMP9 964/4885MMP1 1030/4885MMP13 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.